AI drug discovery market seen topping $7.4B by 2030

The Business Research Company projects the artificial intelligence in drug discovery market will exceed $7 billion by 2030, driven by faster drug development, deeper partnerships and rapid adoption in Asia-Pacific. NVIDIA led the market in 2025 as the sector shifts toward natural language processing and generative AI tools.

Why it matters: - Artificial intelligence is moving from a support tool to a core part of drug discovery workflows. - The market is projected to surpass $7 billion by 2030, signaling rising spending on faster and more cost-efficient pharmaceutical research. - Asia-Pacific is expected to become the largest regional market, which could shift where drug-discovery investment and infrastructure concentrate.

What happened: - The Business Research Company released its Artificial Intelligence in Drug Discovery Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the market will reach more than $7 billion by 2030 and grow at a 26% compound annual rate through the end of the decade. - NVIDIA Corporation led the global market in 2025 with a 6% share. - The top 10 companies held 23% of revenue in 2025, according to the report.

The details: - Asia-Pacific is forecast to reach $2.3 billion by 2030, up from $0.6 billion in 2025, for a 31% CAGR. - The United States is projected to remain the largest country market, growing from $0.8 billion in 2025 to $2.0 billion in 2030 at a 20% CAGR. - Natural language processing is expected to dominate by 2030, accounting for 43% of the market and about $3 billion in value. - The market is also segmented across context-aware processing and deep learning, along with small-molecule and large-molecule drug types. - Therapeutic focus areas include metabolic diseases, cardiovascular disease, oncology, neurodegenerative diseases, anti-infective diseases and respiratory diseases. - End users include pharmaceutical companies, biopharmaceutical firms and academic and research institutes. - The report says demand for quicker and more cost-efficient drug development is one of the main growth drivers. - AI platforms are being used to analyze biological and chemical data, improve drug-target prediction and streamline lead optimization. - Investment and strategic partnerships are adding momentum, along with advances in machine learning, deep learning and generative AI. - The report says context-aware processing, natural language processing and deep learning could collectively add more than $6 billion in value by 2030. - The Business Research Company added new analytical features in its 2026 reports, including market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables. - The report also notes that the broader AI market is expected to reach about $920 billion by 2030, while the IT industry is projected at $13,788 billion. - The artificial intelligence in drug discovery segment would represent about 0.1% of the overall IT market by 2030.

Between the lines: - The numbers point to a market that is still small relative to AI and IT overall, but growing fast enough to matter to both chipmakers and drug developers. - NVIDIA's lead underscores how computing infrastructure has become central to life-sciences AI. - The dominance of natural language processing suggests the near-term value may come as much from mining scientific literature and clinical data as from direct molecular design. - The report's emphasis on partnerships suggests no single player is likely to control the market end to end.

What's next: - The report expects more deals between AI platform providers and drugmakers as companies try to compress discovery timelines. - Insilico Medicine announced a strategic alliance with Takeda Pharmaceutical in July 2026 to use its Pharma.AI platform across multiple therapeutic areas. - The partnership is aimed at speeding candidate identification, improving research efficiency and supporting clinically differentiated therapies. - The report points to generative AI, multimodal platforms, cloud-based AI infrastructure and foundation models as the main competitive priorities ahead.

The bottom line: - AI drug discovery is still a niche market, but the combination of rapid growth, regional expansion and heavy strategic investment makes it one of the most closely watched areas in life sciences.